doi: 10.1016/S01406736(22)006882 9 HouQHuangJAyansolaHMasatoshiHZhangB
J.ThuretS.et al
We dont blame people for high blood pressure or cancer
However, there are critical distinctions: Rodents have a much higher density of GLP-1 receptors on thyroid C-cells than humans Human thyroid C-cells show minimal GLP-1 receptor expression No causal link between semaglutide and thyroid cancer has been established in human clinical trials involving over 10,000 participants (Bjerre Knudsen et al., 2010, Endocrinology ) A large pharmacovigilance study published in Diabetes Care found no increased risk of thyroid cancer among GLP-1 receptor agonist users compared to other diabetes medications (Bezin et al., 2023, Diabetes Care ) Despite this reassurance, the following patients should avoid semaglutide: Those with a personal history of medullary thyroid carcinoma (MTC) Those with a family history of MTC Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) For patients with common hypothyroidism (typically Hashimotos thyroiditis or post-surgical hypothyroidism), these contraindications do not apply
however, residual confounding related to diet, weight loss magnitude, or lifestyle modification cannot be entirely excluded
This is because it can slow down the digestion of carbohydrates, which helps to prevent rapid spikes in blood sugar after eating
